{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:37:43Z","timestamp":1786120663709,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pbb.2026.174247","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:10:04Z","timestamp":1785132604000},"page":"174247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Concurrent mGlu2-mGlu4 receptor positive allosteric modulation for L-DOPA-induced treatment-induced complications in the parkinsonian marmoset"],"prefix":"10.1016","volume":"267","author":[{"given":"Imane","family":"Frouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Belliveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woojin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-6752","authenticated-orcid":false,"given":"Adjia","family":"Hamadjida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-0215","authenticated-orcid":false,"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-8334","authenticated-orcid":false,"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2026.174247_bb0005","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00213-016-4501-9","article-title":"From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders","volume":"234","author":"Acri","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41531-025-01138-1","article-title":"Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson's disease","volume":"11","author":"Alborghetti","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.pbb.2026.174247_bb0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2026.174247_bb0020","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-020-02247-2","article-title":"The MPTP-lesioned marmoset model of Parkinson\u2019s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results","volume":"127","author":"Beaudry","year":"2020","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.pbb.2026.174247_bb0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neuropharm.2012.03.022","article-title":"Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson\u2019s disease treatment and dyskinesia","volume":"66","author":"Bennouar","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2012.05.017","article-title":"Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex","volume":"66","author":"Bogenpohl","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105697","article-title":"Striatal glutamatergic hyperactivity in Parkinson\u2019s disease","volume":"168","author":"Campanelli","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2026.174247_bb0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1042\/BST20140006","article-title":"Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson\u2019s disease","volume":"42","author":"Cenci","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.pbb.2026.174247_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2018.03.027","article-title":"mGlu4 allosteric modulation for treating Parkinson's disease","volume":"135","author":"Charvin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0050","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mds.27462","article-title":"An mGlu4-positive allosteric modulator alleviates parkinsonism in primates","volume":"33","author":"Charvin","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbb.2026.174247_bb0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2026.174247_bb0065","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/13543784.2020.1839047","article-title":"A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson\u2019s disease: translational gaps or a failing industry innovation model?","volume":"29","author":"Doller","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.pbb.2026.174247_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3233\/JPD-230296","article-title":"Metabotropic glutamate receptor 4 (mGlu4) positive allosteric modulators lack efficacy in rat and marmoset models of L-DOPA-induced dyskinesia","volume":"14","author":"Finlay","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.pbb.2026.174247_bb0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson\u2019s disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"issue":"Suppl. 3","key":"10.1016\/j.pbb.2026.174247_bb0080","first-page":"S2","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0085","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0090","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease. The French Clozapine Parkinson Study Group","volume":"353","author":"French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2026.174247_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174452","article-title":"Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"910","author":"Frouni","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00702-020-02287-8","article-title":"Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"128","author":"Frouni","year":"2021","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.pbb.2026.174247_bb0110","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00213-023-06428-1","article-title":"Effect of the mGlu(4) positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"240","author":"Frouni","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0115","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2174\/1570180815666181017131349","article-title":"Challenges in the discovery and optimization of mGlu2\/4 heterodimer positive allosteric modulators","volume":"16","author":"Fulton","year":"2019","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.pbb.2026.174247_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127212","article-title":"Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu(2\/4) heterodimeric receptor results in a compound with mGlu(2\/2) homodimer selectivity","volume":"30","author":"Fulton","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2026.174247_bb0125","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/ejn.14679","article-title":"The highly selective mGlu2 receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease","volume":"51","author":"Hamadjida","year":"2020","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2026.174247_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00002018-199819010-00002","article-title":"Safety of selegiline (deprenyl) in the treatment of Parkinson\u2019s disease","volume":"19","author":"Heinonen","year":"1998","journal-title":"Drug Saf."},{"key":"10.1016\/j.pbb.2026.174247_bb0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0140","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"Hoglinger","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pbb.2026.174247_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/nmt-2023-0016","article-title":"Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease","volume":"13","author":"Huot","year":"2023","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.pbb.2026.174247_bb0155","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson\u2019s disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2015.02.023","article-title":"Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson\u2019s disease and L-DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist","volume":"95","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0165","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1021\/jm034015u","article-title":"Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine","volume":"46","author":"Johnson","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2026.174247_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0175","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.111.187443","article-title":"The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson\u2019s disease","volume":"340","author":"Jones","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2026.174247_bb0180","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.01.014","article-title":"The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys","volume":"78","author":"Justinova","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2026.174247_bb0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1124\/jpet.114.214437","article-title":"Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders","volume":"350","author":"Kalinichev","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2026.174247_bb0190","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.112.078501","article-title":"Functional and pharmacological characteristics of metabotropic glutamate receptors 2\/4 heterodimers","volume":"82","author":"Kammermeier","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0195","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00210-023-02587-2","article-title":"The mGluR(2\/3) orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"396","author":"Kang","year":"2023","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0200","doi-asserted-by":"crossref","first-page":"8917","DOI":"10.1007\/s00210-024-03215-3","article-title":"Positive allosteric mGluR(2) modulation with BINA alleviates dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset","volume":"397","author":"Kang","year":"2024","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108465","article-title":"Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson\u2019s disease","volume":"186","author":"Kwan","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174247_bb0210","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00210-021-02090-6","article-title":"Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset","volume":"394","author":"Kwan","year":"2021","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0215","first-page":"1","article-title":"Metabotropic glutamate receptors in Parkinson\u2019s disease","volume":"168","author":"Kwan","year":"2023","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.pbb.2026.174247_bb0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/jpet.112.196063","article-title":"A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson\u2019s disease","volume":"343","author":"Le Poul","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2026.174247_bb0225","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41467-024-52822-4","article-title":"Elucidating the molecular logic of a metabotropic glutamate receptor heterodimer","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pbb.2026.174247_bb0230","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pbb.2026.174247_bb0235","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26985","article-title":"Allosteric control of an asymmetric transduction in a G protein-coupled receptor heterodimer","volume":"6","author":"Liu","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.pbb.2026.174247_bb0240","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1073\/pnas.1835724100","article-title":"Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson\u2019s disease treatment","volume":"100","author":"Marino","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2026.174247_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2025.100063","article-title":"Metabotropic glutamate receptor homo- and heterodimers exhibit distinct responses to orthosteric and allosteric ligands","volume":"107","author":"McCullock","year":"2025","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0250","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41589-022-01050-2","article-title":"Nanobody-based sensors reveal a high proportion of mGlu heterodimers in the brain","volume":"18","author":"Meng","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.pbb.2026.174247_bb0255","doi-asserted-by":"crossref","first-page":"8683","DOI":"10.1073\/pnas.93.16.8683","article-title":"The temporal lobe is a target of output from the basal ganglia","volume":"93","author":"Middleton","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2026.174247_bb0260","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25233","article-title":"Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells","volume":"6","author":"Moreno Delgado","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.pbb.2026.174247_bb0265","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/acschemneuro.6b00036","article-title":"Development and antiparkinsonian activity of VU0418506, a selective positive allosteric modulator of metabotropic glutamate receptor 4 homomers without activity at mGlu2\/4 heteromers","volume":"7","author":"Niswender","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2026.174247_bb0270","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00702-020-02185-z","article-title":"Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset","volume":"127","author":"Nuara","year":"2020","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.pbb.2026.174247_bb0275","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00210-021-02162-7","article-title":"Additive effects of mGluR(2) positive allosteric modulation, mGluR(2) orthosteric stimulation and 5-HT(2A)R antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset","volume":"394","author":"Nuara","year":"2021","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0280","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease","volume":"61","author":"Olanow","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.pbb.2026.174247_bb0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-023-00918-8","article-title":"Parkinson disease psychosis: from phenomenology to neurobiological mechanisms","volume":"20","author":"Pagonabarraga","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.pbb.2026.174247_bb0290","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. The Parkinson Study Group","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2026.174247_bb0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.pbb.2026.174247_bb0300","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0305","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1016\/j.bmcl.2004.09.028","article-title":"Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators","volume":"14","author":"Pinkerton","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pbb.2026.174247_bb0310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11481-016-9655-z","article-title":"The metabotropic glutamate receptor 4 positive allosteric modulator ADX88178 inhibits inflammatory responses in primary microglia","volume":"11","author":"Ponnazhagan","year":"2016","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0315","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pbb.2026.174247_bb0320","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.28970","article-title":"A randomized, double-blind, controlled phase II study of foliglurax in Parkinson\u2019s disease","volume":"37","author":"Rascol","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2026.174247_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178031","article-title":"Effect of the mGlu(2) receptor positive allosteric modulator AZD8529 on L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset","volume":"1005","author":"Shaqfah","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172957","article-title":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"873","author":"Sid-Otmane","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174247_bb0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pbb.2026.174247_bb0340","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1523\/JNEUROSCI.23-18-07218.2003","article-title":"Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse","volume":"23","author":"Valenti","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2026.174247_bb0345","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2026.174247_bb0350","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41422-023-00830-2","article-title":"Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers","volume":"33","author":"Wang","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.pbb.2026.174247_bb0355","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41380-021-01320-w","article-title":"Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia","volume":"27","author":"Wolf","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2026.174247_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abd2319","article-title":"Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu(2)\/mGlu(4) receptor heterodimers","volume":"14","author":"Xiang","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.pbb.2026.174247_bb0365","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1523\/JNEUROSCI.1129-13.2014","article-title":"Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS","volume":"34","author":"Yin","year":"2014","journal-title":"J. Neurosci."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305726001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305726001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:37:34Z","timestamp":1786063054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305726001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":73,"alternative-id":["S0091305726001024"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2026.174247","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent mGlu2-mGlu4 receptor positive allosteric modulation for L-DOPA-induced treatment-induced complications in the parkinsonian marmoset","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2026.174247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"174247"}}